Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
127M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
39M
-
Shares change
-
+39M
-
Total reported value, excl. options
-
$380M
-
Value change
-
+$379M
-
Put/Call ratio
-
0.89
-
Number of buys
-
55
-
Price
-
$10.10
Significant Holders of Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share (NAUT) as of Q2 2021
59 filings reported holding NAUT - Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share as of Q2 2021.
Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share (NAUT) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39M shares
of 127M outstanding shares and own 30.76% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (8.91M shares), Madrona Venture Group, LLC (6.02M shares), RA CAPITAL MANAGEMENT, L.P. (2.47M shares), Comprehensive Financial Management LLC (2.22M shares), Bain Capital Life Sciences Investors, LLC (2M shares), ORBIMED ADVISORS LLC (1.55M shares), Ally Bridge Group (NY) LLC (1.5M shares), Amazon com Inc (1.46M shares), Alyeska Investment Group, L.P. (1.42M shares), and Nantahala Capital Management, LLC (1.19M shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.